Boost Biopharma, Inc.
Early-stage biotechnology company focused on accelerating design and deployment of recombinant protein vaccine antigens and monoclonal antibodies. The company uses a rapid antigen design framework and antigen libraries to support preclinical studies, antibody discovery, scale-up of protein production, and entry into clinical testing. Headquarters in Woburn, Massachusetts and research laboratory facilities in Madison, Wisconsin.
Industries
N/A
Nr. of Employees
small (1-50)
Boost Biopharma, Inc.
Headquarters: Woburn, Massachusetts; Research laboratory facilities: Madison, Wisconsin. Contact form: https://www.boostbiopharma.com/contact
Patents
Recombinant polypeptides containing at least one immunogenic fragment and uses thereof
US-12409219-B2
View DetailsRecombinant polypeptides containing at least one immunogenic fragment and antibody fc region and uses thereof
US-11358990-B2
View Details
Recombinant polypeptides containing at least one immunogenic fragment and uses thereof
US-12409219-B2
View DetailsRecombinant polypeptides containing at least one immunogenic fragment and antibody fc region and uses thereof
US-11358990-B2
View DetailsProducts
Recombinant SARS‑CoV‑2 protein antigen candidate (clinical)
Next-generation recombinant protein antigen for SARS‑CoV‑2 being evaluated in Phase 1 clinical trials for adjuvanted intramuscular, adjuvant-free intramuscular, and adjuvant-free intranasal administration.
Monoclonal antibody candidates targeting conserved viral epitopes
Monoclonal antibodies generated against engineered antigens with reported cross-variant neutralization activity; intended for prophylactic and therapeutic use and for diagnostic applications.
Antigen libraries and rapid-update antigen frameworks
Collections of antigen sequences and framework families designed for fast update and deployment against evolving pathogen strains.
Recombinant SARS‑CoV‑2 protein antigen candidate (clinical)
Next-generation recombinant protein antigen for SARS‑CoV‑2 being evaluated in Phase 1 clinical trials for adjuvanted intramuscular, adjuvant-free intramuscular, and adjuvant-free intranasal administration.
Monoclonal antibody candidates targeting conserved viral epitopes
Monoclonal antibodies generated against engineered antigens with reported cross-variant neutralization activity; intended for prophylactic and therapeutic use and for diagnostic applications.
Antigen libraries and rapid-update antigen frameworks
Collections of antigen sequences and framework families designed for fast update and deployment against evolving pathogen strains.
Services
Design and engineering of recombinant protein antigens and antigen families for vaccine and antibody applications.
Generation of monoclonal antibodies using engineered antigens for therapeutic and diagnostic use cases.
Support for preclinical testing and initiation of clinical phase 1 testing for recombinant protein vaccine candidates.
Design and engineering of recombinant protein antigens and antigen families for vaccine and antibody applications.
Generation of monoclonal antibodies using engineered antigens for therapeutic and diagnostic use cases.
Support for preclinical testing and initiation of clinical phase 1 testing for recombinant protein vaccine candidates.
Expertise Areas
- Protein engineering for vaccines
- Monoclonal antibody discovery and development
- Recombinant protein expression and purification
- Rapid antigen design and platform development
Key Technologies
- Recombinant protein expression
- Multimeric protein subunit antigens
- Antigen design frameworks (rapid update workflows)
- Monoclonal antibody generation
News & Updates
Link to CEPI coverage describing collaborative efforts to rapidly make new vaccine antigens.
Public health organizations providing financial support, preclinical services, and clinical services for antigen development and clinical testing.
Advancement of a recombinant protein antigen into Phase 1 clinical testing across multiple formulations and routes of administration.
Link to CEPI coverage describing collaborative efforts to rapidly make new vaccine antigens.
Public health organizations providing financial support, preclinical services, and clinical services for antigen development and clinical testing.
Advancement of a recombinant protein antigen into Phase 1 clinical testing across multiple formulations and routes of administration.